RxDoctor Payments Data

Justin Harberson, MD

Gastroenterology · Lancaster, PANPI 1922284652

Payments from drug & device makers

$12,649in general payments, 2019–2025

Across 194 payments — averaging $65.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$11K
  • Madrigal Pharmaceuticals$214
  • Phathom Pharmaceuticals, Inc.$212
  • Pfizer$201
  • Takeda Pharmaceuticals U.S.A., Inc.$187
  • Bristol Myers Squibb$156
  • plus $658 from 14 others

What the payments were for

  • Speaking & faculty fees$6,80054%
  • Travel & lodging$1,85215%
  • Food & beverage$3,99732%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,649 in reported general payments places this provider in the 75th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$134,330
Medicare patients
523
Services billed
2,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin17$51,889
LinzessLinaclotide23$32,970
Mesalamine39$27,238
MotegrityPrucalopride Succinate17$18,486
Dexlansoprazole DrDexlansoprazole33$13,698
IbsrelaTenapanor Hcl11$11,927
MovantikNaloxegol Oxalate13$6,635
Sucralfate15$2,992
Mesalamine ErMesalamine11$2,745
Budesonide EcBudesonide19$2,727
Omeprazole229$2,642
Pantoprazole Sodium135$2,172
Famotidine203$2,116
Colestipol Hcl18$2,023
Esomeprazole Magnesium46$1,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$131$51,88917 claims
AbbVieLinzess$11,021$32,97023 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$187$18,48617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →